However, even though high expression of CD133 in triple negative MDA-MB-231 breast cancer cells is related to a great invasion capability, studies suggest that CD133 can be used as another target for immunotherapy [52,53,54,62]. This evidence concerns the gene PROM1 and breast cancer.